Over the past 12 months, 0 insiders at Icosavax, Inc. filed 0 open-market SEC Form 4 transactions on ICVX: 0 purchases worth $0 and 0 sales worth $0. Insiders have been mixed over this period. The most recent filing was on .
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 1, 24 | Adam K. SimpsonChief Executive Officer | SELL | 15.0K | $15.29 | $229K |
| Jan 2, 24 | Adam K. SimpsonChief Executive Officer | SELL | 15.0K | $15.67 | $235K |
| Dec 21, 23 | Adam K. SimpsonChief Executive Officer | SELL | 50.0K | $15.44 | $772K |
| Dec 20, 23 | Cassia CearleyChief Business Officer | SELL | 7.9K | $15.46 | $123K |
| Dec 20, 23 | Niranjan Kanesa-thasanChief Medical Officer | SELL | 11.9K | $15.46 | $184K |
| Dec 20, 23 | Thomas Joseph RussoChief Financial Officer | SELL | 10.8K | $15.47 | $166K |
| Dec 20, 23 | Adam K. SimpsonChief Executive Officer | SELL | 62.2K | $15.46 | $962K |
| Dec 13, 23 | Cassia CearleyChief Business Officer | SELL | 8.8K | $16.01 | $140K |
| Jul 31, 23 | Cassia CearleyChief Business Officer | SELL | 1.9K | $8.86 | $17K |
| Jul 31, 23 | Niranjan Kanesa-thasanChief Medical Officer | SELL | 3.3K | $8.86 | $29K |
| Jul 31, 23 | Thomas Joseph RussoChief Financial Officer | SELL | 3.1K | $8.86 | $27K |
| Jul 31, 23 | Adam K. SimpsonChief Executive Officer | SELL | 11.8K | $8.86 | $104K |
| Jul 3, 23 | Douglas HoltzmanChief Scientific Officer | SELL | 14.3K | $9.59 | $125K |
| May 23, 23 | Cassia CearleyChief Business Officer | SELL | 10.0K | $10.00 | $100K |
| Apr 3, 23 | Douglas HoltzmanChief Scientific Officer | SELL | 20.1K | $6.56 | $122K |
| Mar 6, 23 | Cassia CearleyChief Business Officer | SELL | 5.0K | $7.75 | $39K |
| Feb 14, 23 | Douglas HoltzmanChief Scientific Officer | SELL | 3.3K | $10.17 | $34K |
| Feb 13, 23 | Elizabeth BekirogluGeneral Counsel & Corp. Sec. | SELL | 5.9K | $10.69 | $63K |
| Feb 13, 23 | Cassia CearleyChief Business Officer | SELL | 1.7K | $10.69 | $18K |
| Feb 13, 23 | Douglas HoltzmanChief Scientific Officer | SELL | 1.5K | $10.69 | $16K |
| Feb 13, 23 | Niranjan Kanesa-thasanChief Medical Officer | SELL | 1.8K | $10.69 | $19K |
| Feb 13, 23 | Thomas Joseph RussoChief Financial Officer | SELL | 1.9K | $10.69 | $20K |
| Feb 13, 23 | Adam K. SimpsonChief Executive Officer | SELL | 7.5K | $10.69 | $80K |
| Jan 4, 23 | Niranjan Kanesa-thasanChief Medical Officer | SELL | 106.4K | $15.70 | $1.7M |
| Dec 21, 22 | Adam K. SimpsonChief Executive Officer | SELL | 66.8K | $8.96 | $598K |
| Dec 15, 22 | Douglas HoltzmanChief Scientific Officer | SELL | 19.6K | $11.14 | $219K |
| Sep 8, 22 | Elizabeth BekirogluGeneral Counsel & Corp. Sec. | SELL | 1.8K | $4.87 | $9K |
| Aug 2, 22 | Cassia CearleyChief Business Officer | SELL | 303 | $6.70 | $2K |
| Aug 2, 22 | Douglas HoltzmanChief Scientific Officer | SELL | 453 | $6.70 | $3K |
| Aug 2, 22 | Niranjan Kanesa-thasanChief Medical Officer | SELL | 543 | $6.70 | $4K |
| Aug 2, 22 | Charles E RichardsonSVP, Technical Operations | SELL | 371 | $6.70 | $2K |
| Aug 2, 22 | Thomas Joseph RussoChief Financial Officer | SELL | 495 | $6.70 | $3K |
| Aug 2, 22 | Adam K. SimpsonChief Executive Officer | SELL | 1.9K | $6.70 | $13K |
| Aug 1, 22 | Cassia CearleyChief Business Officer | SELL | 1.1K | $6.64 | $7K |
| Aug 1, 22 | Douglas HoltzmanChief Scientific Officer | SELL | 9.3K | $6.64 | $62K |
| Aug 1, 22 | Niranjan Kanesa-thasanChief Medical Officer | SELL | 2.0K | $6.64 | $13K |
| Aug 1, 22 | Charles E RichardsonSVP, Technical Operations | SELL | 1.4K | $6.64 | $9K |
| Aug 1, 22 | Thomas Joseph RussoChief Financial Officer | SELL | 1.8K | $6.64 | $12K |
| Aug 1, 22 | Adam K. SimpsonChief Executive Officer | SELL | 7.0K | $6.64 | $47K |
| Jul 29, 22 | Cassia CearleyChief Business Officer | SELL | 391 | $7.11 | $3K |
| Jul 29, 22 | Douglas HoltzmanChief Scientific Officer | SELL | 585 | $7.11 | $4K |
| Jul 29, 22 | Niranjan Kanesa-thasanChief Medical Officer | SELL | 701 | $7.11 | $5K |
| Jul 29, 22 | Charles E RichardsonSVP, Technical Operations | SELL | 479 | $7.11 | $3K |
| Jul 29, 22 | Thomas Joseph RussoChief Financial Officer | SELL | 639 | $7.11 | $5K |
| Jul 29, 22 | Adam K. SimpsonChief Executive Officer | SELL | 2.5K | $7.11 | $17K |
| Apr 1, 22 | Mark McDadeDirector | BUY | 42.2K | $7.10 | $300K |
| Mar 29, 22 | Ra Capital Healthcare Fund LpDirector,TenPercentOwner | BUY | 8.9K | $4.75 | $42K |
| Mar 28, 22 | Ra Capital Healthcare Fund LpDirector,TenPercentOwner | BUY | 175.3K | $4.53 | $794K |
| Mar 7, 22 | Cassia CearleyChief Business Officer | SELL | 9.5K | $17.81 | $163K |
| Aug 2, 21 | Adams Street Partners LlcOther | BUY | 48.0K | $15.00 | $720K |
Over the past 12 months, insiders at Icosavax, Inc. filed 0 open-market purchases worth $0 and 0 sales worth $0 on ICVX, which makes them mixed over the period. The most recent Form 4 was filed on .
The largest recent open-market ICVX insider purchase in our data was $794K by Ra Capital Healthcare Fund Lp, Director,TenPercentOwner, filed on Mar 28, 22.
0 different insiders at Icosavax, Inc. filed open-market SEC Form 4 transactions on ICVX over the last 12 months.
InsiderTape plots every ICVX insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Icosavax, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →